Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.50 |
| ▸ | SRC | P12931 | 15/20 | 0.49 |
| ▸ | SYK | P43405 | 15/20 | 0.49 |
| ▸ | GSK3A | P49840 | 11/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250477 | 0.89 | MAPK14 (0.52) | MAPK14SRCSYKGSK3ABRAF | |
| SCHEMBL5248539 | 0.88 | MAPK14 (0.56) | MAPK14SRCSYKGSK3A | |
| SCHEMBL14459485 | 0.82 | MAPK14 (0.60) | MAPK14SRCSYKGSK3A | |
| SCHEMBL14459488 | 0.81 | MAPK14 (0.60) | MAPK14SRCSYKGSK3A | |
| SCHEMBL5252206 | 0.81 | MAPK14 (0.59) | MAPK14SRCSYKGSK3A | |
| SCHEMBL14459482 | 0.80 | GSK3A (0.68) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6840076 | 0.80 | GSK3A (0.67) | MAPK14SRCSYKGSK3A | |
| SCHEMBL5251975 | 0.79 | MAPK14 (0.61) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6298751 | 0.78 | GSK3A (0.67) | MAPK14SRCSYKGSK3A | |
| SCHEMBL5249406 | 0.78 | MAPK14 (0.60) | MAPK14SRCSYKGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1232150-B1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-10-10 | — | — | EP | claimed |
| US-6492393-B1 | SUCH AS 1-(5-TERT-BUTYL-2-METHOXYPHENYL)-3-(4-(2-METHOXY-PYRIDIN-4YL-OXY)-NAPHTHALEN-1-YL)-UREA; CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | claimed |
| EP-1232150-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001036403-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-05-25 | — | — | WO | claimed |
| EP-1232150-B1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20030125354-A1 | Compounds use as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-6492393-B1 | SUCH AS 1-(5-TERT-BUTYL-2-METHOXYPHENYL)-3-(4-(2-METHOXY-PYRIDIN-4YL-OXY)-NAPHTHALEN-1-YL)-UREA; CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1232150-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001036403-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125354-A1 | Compounds use as anti-inflammatory agents | EPX, MPO, RELA | MAPK14 3716/4885SRC 2161/4885SYK 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.